Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.34 |
| ▸ | LPL | P06858 | 1/20 | 0.34 |
| ▸ | P4HB | P07237 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 3/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16597589 | 0.85 | PRMT5 (0.42) | IRAK4F11PRMT5WDR77F2 | |
| SCHEMBL29547675 | 0.82 | IRAK4 (0.40) | IRAK4LIPGLPLF11PRMT5 | |
| SCHEMBL20120904 | 0.82 | IRAK4 (0.40) | IRAK4LIPGLPLF11PRMT5 | |
| SCHEMBL29547396 | 0.78 | IRAK4 (0.38) | IRAK4LIPGLPLF11PRMT5 | |
| SCHEMBL22907359 | 0.78 | IRAK4 (0.38) | IRAK4LIPGLPLF11PRMT5 | |
| SCHEMBL1702227 | 0.75 | LPL (0.40) | IRAK4LIPGLPLP4HBPRMT5 | |
| SCHEMBL27098819 | 0.75 | ROCK2 (0.39) | IRAK4PRMT5WDR77CCNCCDK8 | |
| SCHEMBL20710303 | 0.75 | IRAK4 (0.35) | IRAK4LIPGLPLF11IDO1 | |
| SCHEMBL23429837 | 0.74 | ELANE (0.31) | F11F2F10DGAT1 | |
| SCHEMBL968588 | 0.72 | LPL (0.42) | IRAK4LIPGLPLF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2024-07-04 | — | — | US | disclosed |
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230086457-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2023-03-23 | — | — | US | disclosed |
| US-20220315575-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-10-06 | — | — | US | disclosed |
| US-11458123-B2 | Tau-protein targeting PROTACs and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| EP-3999182-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| WO-2021011913-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| EP-3535265-A2 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| WO-2018102067-A2 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315575-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | VHL, CRBN, MAPT | IRAK4 4049/4885LIPG 2553/4885LPL 3795/4885 |
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | IRAK4 3852/4885LIPG 2690/4885LPL 3826/4885 |
| US-20230086457-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | IRAK4 4093/4885LIPG 3147/4885LPL 3787/4885 |
| US-11458123-B2 | Tau-protein targeting PROTACs and associated methods of use | CRBN, VHL, UBQLN2 | IRAK4 4093/4885LIPG 3147/4885LPL 3787/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | IRAK4 4093/4885LIPG 3147/4885LPL 3787/4885 |
| US-20240217962-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | VHL, CRBN, MAPT | IRAK4 4049/4885LIPG 2553/4885LPL 3795/4885 |
| US-12559486-B2 | Tau-protein targeting compounds and associated methods of use | UBQLN2, UBQLN1, CRBN | IRAK4 3811/4885LIPG 3319/4885LPL 3194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.